In recent years, histone deacetylase (HDAC) has been a target of cancer therapy because it catalyzes the reversible acetylation of histones and nonhistone substrates to control the epigenetic and transcriptomic landscape of normal and tumor cells [19]. Here, HDAC9 is linked to cancer.